AstraZeneca and Bristol-Myers Squibb Present Results on dapagliflozin at the 46th annual meeting of the European Association for the Study of Diabetes

AstraZeneca and Bristol-Myers Squibb presented results from the study on dapagliflozin at the 46th annual meeting of the European Association for the Study of Diabetes. As per the results of a late-stage clinical trial, dapagliflozin works as effective as a generic drug already present in the market.

According to the phase-3 trial results, AstraZeneca and Bristol-Myers Squibb’s investigational drug dapagliflozin in combination with a widely available generic metformin was as effective as a combination of combglipizide and metformin, or as compared with metformin alone. Patients who were prescribed dapagliflozin experienced weight loss, while patients prescribed with glipizide experienced weight gain and some patients experienced hypoglycaemia.